X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NRL-1049 (previously known as BA-1049), an investigational, phase 1, stage small molecule Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS).
Lead Product(s): NRL-1049
Therapeutic Area: Genetic Disease Product Name: NRL-1049
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2023
Details:
NRL-1049 (previously known as BA-1049), an investigational, phase 1, stage small molecule Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS).
Lead Product(s): NRL-1049
Therapeutic Area: Genetic Disease Product Name: NRL-1049
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
VALTOCO (diazepam) is a nasal spray for acute treatment of episodes of frequent seizures in adult and pediatric patients 6 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL®.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
VALTOCO (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
VALTOCO (diazepam) is a prescription medicine used for the short-term treatment of seizure clusters (also known as “acute repetitive seizures”) in patients 6 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
VALTOCO® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from an individual's usual seizure pattern in adult and pediatric patients 6 years of age and older.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Mean total Quality-of-Life for VALTOCO® (diazepam nasal spray) scores in patients reporting data at one or more timepoints demonstrated a clinically important improvement during the 12-month study.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
VALTOCO® (diazepam) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The VALTOCO® (diazepam nasal spray) CIV, data indicate that patients using the therapy had a statistical and clinically significant increase in the time between their seizure clusters, or SEIzure cluster interVAL (SEIVAL) over a 12-month period.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
VALTOCO (diazepam nasal spray) is a treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from an individual’s usual seizure pattern in adult and pediatric patients 6 years of age and older.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Valtoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
